• Home
  • KyooBe Tech GmbH

KyooBe Tech GmbH

About KyooBe Tech GmbH

Vaccines have become the staple innovation field of the pharmaceutical industry. We want to be at the forefront. Improving production methods and capabilities. Thereby helping pave the road for a healthier future.

We are a young, agile, highly motivated, lateral thinking and interdisciplinary team of biotechnologists, IT experts, engineers and process engineers. Revolutionizing current vaccine production technologies.

KyooBe Tech: Improving pharmaceutical manufacturing – one technology at a time.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • DE
  • 2022
    On CPHI since
  • 25 - 49
    Employees
Company types
Biopharmaceutical company
Engineering
Primary activities
Biopharmaceutical
Laboratory, Analytical, Biotechnology Equipment
Technology
View company profile
Contact info
Show contact info Hide contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024
View Exhibitor Profile

Products from KyooBe Tech GmbH (2)

  • INACTIVATE - I22

    Product INACTIVATE - I22

    INACTIVATE / I22 is a device for the inactivation of pathogens & cells of any kind. By low energy electron irradiation (LEEI) the genetic material of the pathogens & cells is reliably destroyed. The I22 device is suitable for research purposes and small industrial batches. Example use-cases are: Vaccine ...
  • eFit

    Product eFit

    eFIT is a device for the inactivation of pathogens & cells.

    By low energy electron irradiation (LEEI) the genetic material of the pathogens & cells is reliably destroyed. The eFIT platform is suitable for both research (R&D) and small-scale manufacturing companies.
    ...

KyooBe Tech GmbH Resources (1)

  • eFit - Product Detail Page

    Technical Data eFit - Product Detail Page

    eFIT is a device for the inactivation of pathogens and cells in a liquid solution. By low energy electron irradiation (LEEI) the genetic material is reliably destroyed. The eFIT platform is suitable for both research (R&D) and small-scale manufacturing processes.Vaccine productionVirus depletion in process media and blood-derived components incl. sera